Takara Bio Inc. provides consolidated earnings guidance for the fiscal year ending March 31, 2023. The company expects net sales to be JPY 77,800 million, Operating profit to be JPY 19,000 million, profit attributable to owners of parent to be JPY 13,800 million or JPY 114.60 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,012 JPY | -0.10% | -0.30% | -19.17% |
Mar. 18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
Feb. 15 | Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.17% | 790M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- 4974 Stock
- News Takara Bio Inc.
- Takara Bio Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023